172 related articles for article (PubMed ID: 16564141)
1. Development of opioid formulations with limited diversion and abuse potential.
Fudala PJ; Johnson RE
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S40-7. PubMed ID: 16564141
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet.
Cone EJ
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S31-9. PubMed ID: 16458455
[TBL] [Abstract][Full Text] [Related]
4. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
5. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs.
Schuster CR
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S8-14. PubMed ID: 16483729
[TBL] [Abstract][Full Text] [Related]
6. Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?
Raffa RB; Taylor R; Pergolizzi JV
Expert Opin Drug Saf; 2014 Feb; 13(2):181-90. PubMed ID: 24206269
[TBL] [Abstract][Full Text] [Related]
7. Abuse of prescription drugs and the risk of addiction.
Compton WM; Volkow ND
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S4-7. PubMed ID: 16563663
[TBL] [Abstract][Full Text] [Related]
8. Research design strategies to evaluate the impact of formulations on abuse liability.
McColl S; Sellers EM
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S52-62. PubMed ID: 16554125
[TBL] [Abstract][Full Text] [Related]
9. Formulation considerations for the development of medications with abuse potential.
Mansbach RS; Moore RA
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940
[TBL] [Abstract][Full Text] [Related]
10. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.
Cicero TJ; Surratt H; Inciardi JA; Munoz A
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):827-40. PubMed ID: 17636553
[TBL] [Abstract][Full Text] [Related]
11. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.
Butler SF; Black R; Grimes Serrano JM; Folensbee L; Chang A; Katz N
Pain Med; 2010 Jan; 11(1):81-91. PubMed ID: 20002324
[TBL] [Abstract][Full Text] [Related]
12. Abuse deterrent formulations and the Controlled Substances Act (CSA).
Sapienza FL
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S23-30. PubMed ID: 16529882
[TBL] [Abstract][Full Text] [Related]
13. New challenges and opportunities in managing substance abuse in Malaysia.
Mazlan M; Schottenfeld RS; Chawarski MC
Drug Alcohol Rev; 2006 Sep; 25(5):473-8. PubMed ID: 16939945
[TBL] [Abstract][Full Text] [Related]
14. Regulatory challenges for new formulations of controlled substances in today's environment.
McCormick CG
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S63-7. PubMed ID: 16567060
[TBL] [Abstract][Full Text] [Related]
15. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
Webster L
Pain Med; 2009 Jul; 10 Suppl 2():S124-33. PubMed ID: 19691683
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids.
Manchikanti L; Singh A
Pain Physician; 2008 Mar; 11(2 Suppl):S63-88. PubMed ID: 18443641
[TBL] [Abstract][Full Text] [Related]
17. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital.
Cunningham CO; Sohler NL; McCoy K; Kunins HV
Fam Med; 2006 May; 38(5):336-40. PubMed ID: 16673195
[TBL] [Abstract][Full Text] [Related]
18. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
McCann DJ
Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
[TBL] [Abstract][Full Text] [Related]
19. Current approaches in tamper-resistant and abuse-deterrent formulations.
Mastropietro DJ; Omidian H
Drug Dev Ind Pharm; 2013 May; 39(5):611-24. PubMed ID: 22537282
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
Winstock AR; Lea T; Sheridan J
Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
